QT prolongation, a classic risk factor for arrhythmias, can result from a mutation in one of the genes governing cardiac repolarization and also can result from the intake of a medication acting as blocker of the cardiac K ϩ channel human ether-a-gogo-related gene (HERG). Here, we identified the arrhythmogenic potential of a nonopioid antitussive drug, clobutinol. The deleterious effects of clobutinol were suspected when a young boy, with a diagnosis of congenital long QT syndrome, experienced arrhythmias while being treated with this drug. Using the patch-clamp technique, we showed that clobutinol dose-dependently inhibited the HERG K ϩ current with a half-maximum block concentration of 2.9 M. In the proband, we identified a novel A561P HERG mutation. Two others long QT mutations (A561V and A561T) had been reported previously at the same position. None of the three mutants led to a sizeable current in heterologous expression system. When coexpressed with wildtype (WT) HERG channels, the three Ala561 mutants reduced the trafficking of WT and mutant heteromeric channels, resulting in decreased K ϩ current amplitude (dominant-negative effects). In addition, A561P but not A561V and A561T mutants induced a ϷϪ11 mV shift of the current activation curve and accelerated deactivation, thereby partially counteracting the dominant-negative effects. A561P mutation and clobutinol effects on the human ventricular action potential characteristics were simulated using the Priebe-Beuckelmann model. Our work shows that clobutinol has limited effects on WT action potential but should be classified as a "drug to be avoided by congenital long QT patients" rather than as a "drug with risk of torsades de pointes".
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QT prolongation is a risk factor in a number of cardiovascular and noncardiovascular diseases. Among these, the congenital form of the long QT syndrome (LQT) associates prolonged rate-corrected QT interval (QTc) with recurrent syncope and sudden cardiac death resulting from torsades de pointes tachyarrhythmias. The long QT syndrome may also result from the effects of numerous chemically unrelated medications (acquired LQT) in patients with pre-existing normal QT or in patients carrying a long QT gene mutation. At the cellular level, prolongation of the QT interval reflects lengthening of the ventricular action potential (AP). In the human heart, a key repolarizing potassium current is the rapidly activating component of the delayed rectifier I Kr (Sanguinetti and Jurkiewicz, 1990) . Its activation initiates repolarization and terminates the plateau phase of the cardiac AP concomitantly to the T wave on the ECG. I Kr is related to pore-forming channel proteins encoded by the human ether-a-go-go-related gene (HERG) Sanguinetti et al., 1995) . Mutations in HERG account for chromosome 7-linked inherited long QT syndrome 2 (LQT2) (Keating, 1995; Sanguinetti et al., 1996) . Finally, the vast majority of drugs that produce the acquired LQT are blockers of HERG channels (Roden et al., 1996) .
In the present work, we have identified the arrhythmogenic potential of a common drug, clobutinol, a centrally acting nonopioid antitussive drug widely used in Europe as treatment for dry cough of infectious origin. The deleterious effects of the molecule were suspected when a young boy, with a diagnosis of LQT2, experienced syncopes and arrhythmias while being treated with clobutinol. We have evaluated the inhibitory potency of clobutinol on wild-type HERG current. In the proband, we identified a novel LQT2 mutation (A561P), which we functionally characterized in recombinant expression system. It is interesting to note that two others mutations (A561V and A561T) at the same position were reported previously Dausse et al., 1996) in patients with congenital LQT2. We thus examined and compared the mechanism for HERG channel dysfunction in each of these three A561 mutations. Our work shows that a common drug not identified previously as a QT-prolonging drug can precipitate the LQT2 syndrome.
Materials and Methods
Clinical Studies. The proband, an 11-year-old boy, received a diagnosis of a long QT duration in 1997. In 1999, he developed first symptoms in relation to torsades de pointes upon clobutinol treatment. A familial investigation was initiated. All family members enrolled gave written informed consent. Signature was given by parents in the case of children younger than 18 years. The protocol was approved by the local Committee for the Protection of Human Subjects in Biomedical Research of Nantes University, Nantes, France. Participants were evaluated by history, review of medical records, and 12-lead electrocardiogram. Correction of the duration of the QT interval as a function of cycle length was performed using both Bazett's and Fridericia's formulae (QTc Bazett ϭ QT/2͌RR and QTc Fridericia ϭ QT/3͌RR, with RR expressed in seconds).
Mutation Analysis. Genomic DNA was prepared from peripheral blood lymphocytes by standard methods. Mutation analysis was conducted by direct sequencing of the gene using an ABI 377 automated sequencer (Applied Biosystems, Foster City, CA). Polymerase chain reactions for each of the amplicons representing the entire coding sequence and splicing sites of KCNH2 as well as KCNQ1, KNCE1, and SCN5A genes were performed as described previously (Wang et al., 1995; Splawski et al., 1998) .
Cell Culture and Transfection. African green monkey kidney cells (COS-7) were obtained from the American Type Culture Collection (Manassas, VA). Cells were cultured at 37°C in a 5% CO 2 humidified incubator in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, and antibiotics (100 IU/ml penicillin and 100 g/ml streptomycin) (all from Invitrogen, Carlsbad, CA). Human wild-type HERG cDNA was subcloned into the mammalian expression vector pBK under the control of the cytomegalovirus promoter/enhancer (Stratagene, La Jolla, CA). A561P, A561T, or A561V mutations were introduced using standard molecular techniques. Cells were transfected using the intranuclear microinjection technique or using polyethylenimine (PEI) as a transfection reagent. A green fluorescence protein plasmid (pEGFP; BD Biosciences Clontech, Palo Alto, CA) was used as an inert plasmid to ensure a constant plasmid concentration and also to permit cell detection. The microinjection protocol using the ECET microinjector 5246 system (Eppendorf, Hamburg, Germany) has been described previously by Mohammad-Panah et al. (1998) . Plasmids (3 g/ml pBK-CMV-WT or mutated HERG plus 3 g/ml pEGFP for homomeric channels, and 3 g/ml pBK-CMV-WT HERG plus 3 g/ml pBK-CMV-mutated HERG for heteromeric channels) were diluted in a buffer containing 40 mM NaCl, 50 mM HEPES, and 50 mM NaOH, pH 7.4, and supplemented with 0.5% fluorescein isothiocyanate-dextran (150 kDa). Otherwise, cells were transfected when the culture reached 60 to 80% confluence with plasmids complexed with PEI as reported previously with 2 g of plasmids per milliliter of culture medium. In patch-clamp experiments, we used 20% pBK-CMV-WT or mutated HERG plus 80% pEGFP for homomeric channels and 20% pBK-CMV-WT HERG plus 20% pBK-CMV-mutated HERG and 60% pEGFP for heteromeric channels. For immunolocalization experiments, we used 100% pBK-CMV-WT or mutated HERG for homomeric channels and 50% pBK-CMV-WT HERG plus 50% pBK-CMV-mutated HERG for heteromeric channels.
Patch-Clamp Recordings. Twelve to twenty-four hours after transfection, K ϩ currents from HERG-transfected COS-7 cells were recorded at 35°C using the whole-cell configuration of the patchclamp technique. Cells were placed on the stage of an inverted microscope and continuously superfused with Tyrode's solution. During the current measurements, a microperfusion system allowed local application and rapid change of the different extracellular solutions used to specifically record the K ϩ currents. Patch pipettes with a tip resistance of 2.5 to 5 M⍀ were electrically connected to a patch-clamp amplifier (Axopatch 200A; Axon Instruments Inc., Union City, CA). Stimulation, data recording, and analysis were performed through an A/D converter (Tecmar TM100 Labmaster; Scientific Solutions, Mentor, OH) using Acquis1 software (Bio-Logic, Claix, France). Wild-type (WT) and mutant HERG currents were measured using the following voltage protocol. The membrane potential was clamped at a holding potential of Ϫ90 mV, and every 3 s, a voltage prepulse to ϩ10 mV was applied for 500 ms followed by the test pulse to Ϫ70 mV for another 500 ms. The deactivating K ϩ current (or tail current) was measured during polarization to Ϫ70 mV and normalized for each cell using the cell capacitance. To evaluate the current activation, the prepulse voltage varied from Ϫ100 to ϩ60 mV for 500 ms. To evaluate the deactivation kinetics, the voltage test pulse varied from Ϫ70 to Ϫ40 mV. Recorded human subendocardiac action potential acquired at 1000-ms pacing length was also used to clamp the cells.
Immunolocalization Experiments. Cells were plated 12 h after transfection on coverslips, left for 48 h in the incubator to allow protein expression, and then fixed in 4% phosphonoformatic acid, permeabilized in 0.1% Triton X-100, and incubated overnight at 4°C with a rabbit anti-erg antibody (1:1000; Alomone Labs, Jerusalem, Israel) in 1% bovine serum albumin. Cells were rinsed in phosphatebuffered saline and incubated for 1 h at room temperature with a fluorescein isothiocyanate-conjugated goat anti-rabbit antibody (1: 200; Sigma-Aldrich, St. Louis, MO). Cells were mounted between slips and coverslips and placed on the stage of an inverted TCS NT confocal microscope (Leica, Wetzlar, Germany). Cells were observed using a ϫ63 oil objective.
Solutions and Drugs. Tyrode's solution used for patch-clamp experiments contained 145 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5 mM HEPES, and 5 mM glucose, pH 7.4. The standard extracellular solution to record K ϩ current contained 145 mM sodium gluconate, 4 mM potassium gluconate, 7 mM hemi-calcium gluconate (free Ca 2ϩ : 1), 4 mM hemi-magnesium gluconate (freeMg 2ϩ : 1), 5 mM HEPES, 5 mM glucose, and 20 mM mannitol, pH 7.4. Patch-clamp pipettes contained 145 mM potassium gluconate, 2 mM K 2 ATP, 2 mM hemi-magnesium gluconate (free-Mg 2ϩ : 0.1), 5 mM HEPES, and 2 mM EGTA, pH 7.2. Free activities were calculated using a software designed by G. L. Smith (University of Glasgow, Glasgow, UK). Clobutinol (SILOMAT 20 mg/2 ml solution; Boehringer Ingelheim GmbH, Ingelheim, Germany) was diluted in extracellular solution as a 10 Ϫ4 M stock solution. The test solutions were prepared by further successive dilutions. E-4031 was prepared as a 10 Ϫ3 M stock solution with distilled water. Computer Modeling. Functional effects of the HERG mutations were tested by computer simulations using the Priebe-Beuckelmann human ventricular cell model (Priebe and Beuckelmann, 1998) . The experimentally observed Ϸ70% reduction in HERG tail current density was implemented by a 70% decrease in the fully activated conductance of I Kr . The experimentally observed Ϫ11 mV shift in voltage dependence of WT ϩ A561P HERG current activation was incorporated by a Ϫ11 mV shift in the I Kr steady-state activation curve, whereas the Ϸ30% decrease in the fast and slow time constants of HERG channel deactivation were implemented by a 30% decrease in the corresponding I Kr time constant. Action potentials were elicited by repetitive stimulation with a 2-ms, Ϸ20% suprathreshold stimulus current.
The Priebe-Beuckelmann model produces an action potential that is typical for an epicardial cell. To obtain endocardial and M cell models, we reduced the current densities of the transient outward current (I to ), the slow component of the delayed rectifier current (I Ks ), and the inward rectifier current (I K1 ) in the Priebe-Beuckelmann model by 75, 8, and 11%, and by 13, 54, and 26%, respectively (Conrath et al., 2004) , from canine and human data (Liu et al., 1993; Liu and Antzelevitch, 1995; Nä bauer et al., 1996) .
To measure restitution of action potential duration (APD restitution) in the single human ventricular cell model, we used an S1-S2 stimulus protocol (Qu et al., 1999) . After a period of pacing at a basic S1-S1 pacing interval of 1000 ms, S2 was applied after a variable S1-S2 interval. The strengths of the 2-ms S1 and S2 stimuli were fixed at 2.5 times threshold, and APD was defined using a threshold voltage of Ϫ77.2 mV, which is near the voltage at which the action potential is 90% repolarized.
Models were coded using Compaq Visual Fortran 6.6 and run on a 3-GHz Intel Pentium 4 processor workstation, applying a Euler-type integration scheme with a 5-s step. All simulations were run for a sufficiently long time to reach steady-state behavior.
Statistics. All data are presented as mean Ϯ S.E.M. Statistical significance of the observed effects was assessed by means of the Student's t test, Mann-Whitney rank sum test, or two-way analysis of variance when appropriate. A value of p Ͻ 0.05 was considered significant.
Results
Clinical Characteristics. The proband, a boy born in 1992, received a diagnosis for a tetralogy of Fallot and had surgery several years before the drug-induced arrhythmia. His ECG follow-up is illustrated in Fig. 1A , a to d. Lengthening of the QT interval (QTc Bazett ϭ 628 ms and QTc Fredericia ϭ 597 ms) was initially detected in 1997 in the absence of associated symptoms (Fig. 1Aa) . In 1999, he experienced for the first time syncope and torsades de pointes arrhythmias during treatment with clobutinol, a common antitussive drug (Fig. 1Ab) . The baseline serum K ϩ level indicated a moderate hypokalemia to 3.5 mM before any treatment (February 5, 1999) . However, the arrhythmic episodes did not cease under potassium, magnesium, or ␤-blocker therapy, even when the serum potassium was normalized to 4.1 mM. Torsades de pointes only ceased when the heart was paced. After clobutinol treatment was discontinued, the QTc interval progressively decreased to pretreatment values with a time course comparable with clobutinol half-life (23-32 h) (Zimmer et al., 1977) (Fig. 1Ac ). The kidney function was considered to be normal from urea and creatinine levels [February 5, 1999: 1.8 mM (blood urea nitrogen, 5 mg/dl) and 44 mg/dl, respectively]. After 1999, the proband had no further arrhythmia or symptoms, although he has retained a long QTc interval (Fig.  1Ad) . Together, these data correlate the clobutinol intake to the torsades de pointes episodes. Repolarization abnormalities were also detected in his asymptomatic father (Fig. 1B ) and in his elder brother (Fig. 1C) . Neither the brother nor the father has had a history of cardiac surgery. The other relatives, including his mother (Fig. 1D ), presented normal ECG findings.
Mutation Analysis. DNA sequencing of exon 7 in the proband (III-1; Fig. 2 ) identified a heterozygous G-to-C mutation at position 1681. This missense mutation was predicted to change an alanine for a proline (A561P) within the S5 region of HERG. This mutation was also identified in the proband's father and in his elder brother (II-1 and III-2). DNA sequencing of other genes related to LQT (i.e., KCNQ1, KCNE1, and SCN5A) encoding the ␣-and ␤-subunits of the I Ks current and the ␣-subunit of the I Na channel, respectively, did not reveal other mutations.
Clobutinol Blocks HERG Current. We investigated the sensitivity of homomeric WT channels to the nonopioid antitussive clobutinol. Transfected COS-7 cells expressed a large K ϩ current, with biophysical properties reminiscent of those of the rapid component of the cardiac delayed-rectifier K ϩ current recorded in human cardiac cells (Fig. 3A) (Wang et al., 1994) . When repolarized to Ϫ70 mV, expressing COS-7 cells exhibited a large deactivating current (I tail). The halfactivation potential (V 1/2 ) for this current was calculated as Ϫ10.4 Ϯ 5 mV (n ϭ 10). Clobutinol at 10 Ϫ5 M induced a slow decay of the activating current recorded at ϩ10 mV suggesting, voltage-dependent block and a lesser blocking effect at the initial phase of activation. This pattern of inhibition was observed at the steady state. After full activation at ϩ10 mV, clobutinol inhibited the HERG tail current with a half-maximum block concentration (IC 50 ) of 2.9 ⅐ 10 Ϫ6 Ϯ 0.7 ⅐ 10 Ϫ6 M and a Hill coefficient of 0.9 (n ϭ 9) (Fig. 3B) .
As illustrated in Fig. 3C , the HERG-related K ϩ current activated at potentials positive to Ϫ50 mV and exhibited strong inward rectification. Deactivating K ϩ currents reached a maximum after a prepulse to 10 mV and did not further increase with more positive depolarizing prepulses (Fig. 3D) . As depicted in Fig. 3 , C and D, clobutinol decreased activating and deactivating currents. The inset in Fig. 3D shows that clobutinol blocked the tail current more effectively at depolarized potentials (p Ͻ 0.001). Recovery from block was also analyzed when the membrane potential was repolarized to Ϫ70 mV. After a depolarization to ϩ10 mV, the initial deactivating current measured at the beginning of the repolarizing pulse (I tail init) was significantly more inhibited than that measured 500 ms later (I tail late) (10 Ϫ5 M clobutinol, 71 Ϯ 5 versus 45 Ϯ 13%; inhibition percentage of I tail init and I tail late, respectively; n ϭ 7, p Ͻ 0.05). We conclude that the HERG block as produced by clobutinol was voltage-dependent inasmuch as it was more pronounced at depolarizing voltages and as it developed with depolarization and relaxed with repolarization.
Electrophysiological Properties of the HERG A561P, HERG A561T, and HERG A561V Channels. Because the nonopioid antitussive drug clobutinol had triggered arrhythmias in the A561P HERG carrier, we evaluated the effects of this mutation on the channel function. The functional effects of A561P were also compared with those caused by A561T and A561V mutations. In cells injected into the nucleus with either A561P HERG, A561T HERG, or A561V HERG, no current was recorded, unlike in cells injected with WT HERG, suggesting that the three mutations led to a complete loss of function (Fig. 4A ). Because patients with LQT are Fig. 2 . Pedigree of the family. Empty symbols (circles, female family members; squares, male family members) depict unaffected members, gray symbols depict members presenting a long QTc only, and the black symbol represents the member who experienced torsades de pointes. ϩ, carriers of A561P HERG mutation; Ϫ, noncarriers. Fig. 3 . A, effects of clobutinol on HERG K ϩ currents expressed in COS-7 cells. Representative current traces recorded in cells expressing WT HERG in control condition and in the presence of increasing clobutinol concentrations. Voltage protocol (500-ms steps) was as shown in the inset. B, dose-response curve for clobutinol to block the HERG tail current (n ϭ 9). Voltage protocol used was the same as that described in A. Tail current was normalized to the control value and expressed as a function of the drug concentration. Solid line, fit of experimental data to the Hill equation y ϭ a ϩ {d/[1 ϩ (x/c)
n H ]}, where x is the drug concentration and n H is the Hill coefficient. IC 50 value was calculated as the drug concentration for which y ϭ 50%. ૺૺ, p Ͻ 0.01; ૺૺૺ, p Ͻ 0.001. C, current-voltage relation for activated current (prepulse current, I pp ) density in control (I pp /C m ; E) and in the presence of 2.10 Ϫ6 M clobutinol (F; n ϭ 10). Voltage protocol consisted of 500-ms depolarizing and hyperpolarizing prepulses to various potentials between Ϫ100 and ϩ60 mV followed by a test pulse to Ϫ70 mV for 500 ms. Holding potential, Ϫ90 mV; frequency, 0.33 Hz. D, current-voltage relation for the deactivating tail current (I tail ) density under control conditions (I tail /C m ; E) and with 2.10 Ϫ6 M clobutinol (F; n ϭ 10). ૺૺૺ, p Ͻ 0.001. Inset, inhibition ratio (1 Ϫ [I tail in the presence of 2.10 Ϫ6 M clobutinol/I tail control]) versus prepulse potential (n ϭ 9 -10).
heterozygous for these HERG mutations, mutant and WT proteins were coexpressed with appropriate ratios to mimic the genotype of the mutation carriers. As shown in Fig. 4B , the tail K ϩ current density measured at Ϫ70 mV (depolarizing test pulse to ϩ10 mV) was markedly reduced to approximately 30% of the control current. We concluded that the three mutations altered the WT HERG channel function in a dominant-negative manner.
The absence of measurable K ϩ currents for mutated homomeric channels can be related to either a defect in channel targeting to the plasma membrane or altered gating properties of channels. To test whether homomeric channels are inserted into the cell membrane, immunolocalization experiments were conducted. As illustrated in Fig. 4A , WT HERGexpressing cells showed an intracellular and plasma-membrane staining, whereas membrane staining was undetectable with A561P, A561T, and A561V HERG channels, suggesting that these channels do not insert into the cell membrane. In cells cotransfected with WT and mutant HERG, confocal microscopy revealed that membrane staining was still detectable, although less intensely (Fig. 4B) . These results suggest that the mutated channels are poorly processed to the plasma membrane and that heterotetramers coexpressed with the WT protein are mostly retained in intracellular compartments.
In addition to the strong reduction in current amplitude, the A561P mutation also modified the voltage-dependence of activation of the WT ϩ A561P heteromeric channels (Fig. 5 , A and B) and produced a significant shift of V 1/2 toward more negative potentials (Table 1 ). The small 3-to 3.5-mV shift seen in cells coexpressing WT ϩ A561V or A561T HERG was not significant. On the other hand, the slope factor of activation was slightly but significantly modified, demonstrating Fig. 4 . A, current recorded from WT HERG-, A561P HERG-, A561T HERG-, or A561V HERG-injected COS-7 cells. Voltage protocol used was the same as that described in Fig. 3B . B, tail current density recorded at Ϫ70 mV after a depolarization to ϩ10 mV in cells either injected with cDNA coding for WT HERG or coinjected with WT HERG cDNA plus A561P, A561T or A561V HERG cDNA. Statistical significance versus WT: ૺૺૺ, p Ͻ 0.001. Insets, confocal laser scanning images of COS-7 transfected with the different cDNAs. White arrows, membrane staining. 5 . A, prepulse current density (I pp /C m ) versus potential in cells either injected with WT HERG (n ϭ 13) or coinjected with WT HERG plus A561P HERG (n ϭ 12), A561T HERG (n ϭ 9), or A561V HERG (n ϭ 9). The same voltage protocol was used as described in Fig. 3C . B, relative tail current versus prepulse potential. Inset, representative current traces recorded in cells polarized at Ϫ100, Ϫ40 (black arrows), 0, ϩ20, and ϩ 40 mV (scales: 5 pA/pF and 200 ms) in cells expressing WT HERG or WT ϩ A561P HERG channels. C, the tail current recorded at various potentials after a depolarization to ϩ10 mV was fitted using the equation I (t) ϭ a f exp(Ϫt/ f ) ϩ a s exp(Ϫt/ s ), where a f and a s represent the respective proportion of the fast ( f ) and slow ( s ) deactivation processes.
f (bottom) and s (top) are plotted as a function of test pulse potential for HERG WT tail currents (n ϭ 13) and for WT ϩ A561P HERG tail currents (n ϭ 7). Statistical significance versus WT: ૺૺ, p Ͻ 0.01; ૺ, p Ͻ 0.05.
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at ASPET Journals on April 6, 2017 molpharm.aspetjournals.org the alteration of the channel gating induced by the mutations. In cells coexpressing WT ϩ A561P HERG, we also observed a reduction in the fast and slow deactivation time constants when the deactivating current traces were fitted using a double exponential function (Fig. 5C ). The fast deactivating component contributed to approximately 40% of the WT or WT ϩ A561P current at any tested potential. Altogether, the modifications as induced by the A561P mutation (i.e., current reduction and faster deactivation kinetics counterbalanced by the shift in the activation curve) should lead to a milder loss of function of the WT ϩ A561P channels compared with the A561V or A561T mutations, which only produced a decrease in current amplitude.
To visualize more accurately the functional effects of the mutants, a human ventricular action potential voltage clamp wave form was applied to cells expressing WT or WT ϩ mutated HERG channels. The normalized currents resulting from this stimulation are depicted in Fig. 6 . The HERG current, shown as the E-4031-sensitive current, increased progressively as the action potential repolarized to reach a peak. In accordance with the shift of the activation curve of WT ϩ A561P channels, an earlier WT ϩ A561P HERG current peak was seen during the action potential time course. This behavior should presumably lead to a less pronounced QT interval lengthening in comparison with WT ϩ A561T or WT ϩ A561V channels.
Clobutinol Blocks WT ؉ A561P HERG Current. The effects of clobutinol were further tested in cells coexpressing WT ϩ A561P HERG channels. Figure 7 illustrates that the sensitivity of heteromeric channels to the block produced by clobutinol was similar to that of homomeric channels (IC 50 for clobutinol on heteromeric WT ϩ A561P HERG, 1.9 10 Ϫ6 Ϯ 0.7 10 Ϫ6 M; Hill coefficient, 1.1; n ϭ 5). Functional Implications. Electrophysiological data demonstrate that each of the WT ϩ A561P, WT ϩ A561T, and WT ϩ A561V HERG currents is characterized by a decrease in current density to Ϸ30% of the control WT value. In addition, the WT ϩ A561P HERG current shows alterations in kinetics (i.e., a Ϫ11 mV shift in voltage dependence) of activation as well as a Ϸ30% decrease in fast and slow time constants of deactivation. To assess the functional consequences of these alterations, we carried out computer simulations using the comprehensive human ventricular cell model by Priebe and Beuckelmann (1998) . Figure 8A (top) shows the model action potential with normal I Kr (broken line) and with a 70% reduction in I Kr (solid line), representing the experimentally observed reduction in HERG current density. The reduction in repolarizing current induces a prolongation of the action potential by 124 ms (arrow). The experimentally observed alterations in kinetics result in an earlier activation of HERG channels and thus in a larger I Kr amplitude (Fig. 8B) . Despite the more rapid deactivation of the current, repolarization is accelerated and the action potential shortened by 33 ms. When combined, the two effects (i.e., the reduction in current density and alterations in kinetics) are almost additive, with an AP prolongation of 97 ms (Fig. 8C) . We also tested the effects of the experimentally observed TABLE 1 Activation parameters of WT, WT ϩ A561P, WT ϩ A561T, and WT ϩ A561V HERG currents
Voltage protocol was the same as described in Fig 3C . Tail currents were fitted using a Boltzmann equation: I tail /I tail max ϭ 1/{1 ϩ exp͓Ϫ(V pp Ϫ V 1/2 )/k͔}, where I tail max is peak I tail , V pp is the prepulse potential, V 1/2 is the prepulse voltage for which I tail is half of I tail max , and k is the slope factor. WT was tested versus data obtained when PEI was used as transfection vector (see clobutinol experiments) and WT ϩ A561s versus WT. Fig. 3A . B, dose-response curve for WT ϩ A561P HERG K ϩ tail current (n ϭ 4). Normalization and fitting was done as described in Fig.  3B . changes in slope of the HERG channel-activation curve (Table 1), but the effects thereof were very small, with a change in APD 90 (⌬APD 90 ) typically less than 1 to 2 ms (data not shown). We also determined ⌬APD 90 for pacing cycle lengths other than 1 s (Fig. 8D) . In all cases, the effects are more pronounced at shorter cycle lengths (i.e., at higher heart rate), which was also observed in a canine AP model for other mutations that affect I Kr (Mazhari et al., 2001 ). Figure 8D also shows that the A561P HERG mutation (‚) exerts milder effects than the A561T or A561V mutations (Ⅺ). However, application of clobutinol (simulated by a 30% block of I Kr , in accordance with the estimated circulating drug concentration of 0.55 to 0.75 M and the dose-response curve shown in Fig. 7) (Zimmer et al., 1977) increases AP prolongation for the A561P mutation to values greater than those for the more severe A561T or A561V mutations (Fig. 8D, OE) . With wildtype HERG channels, clobutinol per se produces a mild prolongation of the action potential at all pacing cycle lengths (Fig. 8D, F) .
Increased dispersion of repolarization across the ventricular wall, either arising from dynamic factors (steeper APD restitution) or from enhanced heterogeneity in intrinsic electrophysiological properties among different cell types, is an important determinant of the susceptibility to ventricular arrhythmias (Qu et al., 2000) . Therefore, we first tested whether the HERG channel mutations would steepen the APD restitution curve (Fig. 8E) . Again, the largest effects are observed for the A561T or A561V mutations. However, application of clobutinol significantly steepens the APD restitution curve for the A561P mutation, yielding a slope near 1 for the steepest part of the curve. With wild-type HERG channels, clobutinol produces only moderate alteration in the restitution curve. Next, we assessed the effects of the HERG channel mutations on the intrinsic differences among the different cell types. Figure 8F shows that the mutations preferentially prolong the M cell action potential, thereby increasing the dispersion of repolarization. The largest dispersion is obtained for the WT ϩ A561P HERG current in the presence of clobutinol (189 ms versus a control value of 59 ms). It has been hypothesized that the AP prolongation associated with LQT favors the development of early after-depolarizations (EADs) and triggered activity caused by reactivation of the L-type calcium current (I Ca,L ) during the AP plateau. In contrast with simulation studies using the Luo-Rudy guinea pig-type AP model (Viswanathan and Rudy, 1999) , we did not observe EADs in any of the three cell types studied. As discussed by Priebe and Beuckelmann (1998) , the lower susceptibility of their human ventricular cell model to the generation of EADs could reflect an inherent property of human tissue. We did, however, observe considerably delayed repolarization for the M cell model in the case of the A561 HERG channel mutations, especially in response to moderate increases in I Ca,L , with APD 90 values exceeding 1 s upon a 25% increase in I Ca,L (data not shown).
In summary, Fig. 8 shows that the effects of the A561P mutation on basic AP properties are constantly less severe than those of the A561V or A561T mutation but become more severe if the WT ϩ A561P HERG current is further reduced by the application of clobutinol.
Discussion
This report is the first to detail the effects of clobutinol, a commonly used antitussive drug, on the HERG cardiac K ϩ channel. The rhythmic incident correlated to clobutinol intake in the proband revealed the potential effects of the drug and instigated the present study, which also resulted in the identification of a novel HERG mutation responsible for LQT2.
Drug-Induced Action Potential Prolongation. We found that clobutinol displays an IC 50 of Ϸ2 M on HERG. As illustrated by computer modeling, clobutinol would induce only mild modifications in the ventricular action potential duration of unaffected individuals. The effects of clobutinol displayed a positive voltage dependence, suggesting that the molecule interacts with an activated state of the HERG channel. Drugs that block HERG current, are often associated with QT prolongation and development of the ventricular arrhythmia known as torsades de pointes. Among them are terfenadine, astemizole, and cisapride. Published IC 50 values ranged between 56 and 431 nM for terfenadine (Rampe et al., 1997; Chachin et al., 1999) and between 69 and 480 nM for astemizole (Taglialatela et al., 1998; Chachin et al., 1999) . Cisapride IC 50 values ranged between 4.3 nM in human embryonic kidney 293 cells (Anson et al., 2004) and 124 nM in Xenopus laevis oocytes (Fernandez et al., 2004) . We investigated previously the effects of cisapride and measured an IC 50 value of 240 nM (Potet et al., 2001 ). We and others (Walker et al., 1999) have shown that the inhibition produced by cisapride increases during depolarization and is partially removed during repolarization. In our previous and present works, the cells were depolarized for 500 ms only, a duration close to the human action potential duration but much shorter than the duration used by previous investigators (2-to 20-s duration prepulses). Because cisapride produces a time-dependent open-channel block, the affinity of cisapride for HERG may be overestimated when long depolarization duration protocols are used. Because clobutinol is also a voltage-dependent blocker, it is more accurate to compare clobutinol and cisapride IC 50 values for relatively brief depolarizations. Under these conditions, clobutinol has an IC 50 value that is approximately 10 times higher than that of terfenadine, astemizole, or cisapride. This may explain why clobutinol, despite widespread clinical use in Europe, has not yet been reported to produce QT prolongation. On the other hand, the long QT syndrome may often be missed in patients presenting syncope, seizures, or drop attacks (Pacia et al., 1994) . This may hold for a previously reported case of grand mal seizure associated with clobutinol overdose (Ramirez et al., 1993) . In conclusion, the absence of other case reports involving clobutinol and its relatively high IC 50 value exclude this drug from the list of drugs with risk of torsades de pointes, although the potential inhibitory activity of clobutinol may represent an aggravating factor when the cardiac repolarization reserve is already reduced, as in patients with congenital LQT like the proband in the present study.
Trafficking of Mutant HERG Proteins. Among the mechanisms underlying LQT2, impaired trafficking of HERG protein is increasingly recognized as a leading cause. In vitro, the A561P mutation caused defects in intracellular protein transport to the plasma membrane. Furthermore, the mutant subunit coexpression reduced the WT HERG function by a dominant-negative effect. Similar results were obtained with A561V or A561T HERG, two LQT2 mutations that were identified previously Dausse et al., 1996) . Studying the A561V dominant-negative mechanism, Ficker et al. (2000) observed that coassembly of WT with A561V HERG prevented the traffic of the heteromeric channels to the plasma membrane. Our results are in favor of a similar mechanism concerning A561T or A561P HERG mutants. Numerous HERG mutations leading to trafficking deficiency have been described throughout the protein (Paulussen et al., 2002) . Key regions of the protein for trafficking have been described in the C-terminal part of the protein as well as in the N-terminal-located PAS domain (Kupershmidt et al., 2002; Paulussen et al., 2002; Akhavan et al., 2003) . Retention of mutant proteins has also been associated with increased affinity with the chaperones heat shock protein 70 and heat shock protein 90 (Ficker et al., 2003) . However the amino acids involved in this association are localized in the S5-p-loop linker or in the C-terminal tail, unlike the Ala561.
HERG Channel Mutations at Position 561. Assuming random coassembly of WT and mutant HERG subunits and also that only WT homotetramers are conductive, the K ϩ current resulting from heterozygous expression should be reduced to 1/16 th of the WT current value. Subsistence of a current Ͼ1/16 th of WT K ϩ current indicates that the association of WT and mutated HERG is less frequent than homomeric association or, alternatively, that some heteromeric channels can reach the plasma membrane and effectively conduct K ϩ current. Concerning the A561P mutation, modifications of the heteromeric K ϩ current characteristics (i.e., ϷϪ11-mV shift of the activation V 1/2 and change in deactivation kinetics) are in favor of the second hypothesis. Investigating the effects of A561V HERG mutant, Kagan et al. (2000) suspected a small fraction of current being passed by heteromeric channels. These authors also observed a shift of the activation V 1/2 in Chinese hamster ovary cells from ϩ0.7 mV in WT HERG-expressing cells to Ϫ10.9 mV in WT ϩ A561V HERG-expressing cells. We failed to observe such a ϷϪ10-mV shift in COS-7 cells. It has to be mentioned, however, that the study by Kagan et al. was performed at room temperature, unlike ours (35°C). Studying WT HERG bio-physical properties in human embryonic kidney 293 cells at various temperatures, Zhou et al. (1998) calculated a shift of V 1/2 value from Ϫ14.2 mV at 23°C to Ϫ25.9 mV at 35°C. The latter value is close to that of Ϫ21.5 mV obtained at the same temperature by Sanguinetti and Jurkiewicz (1990) for the native I Kr in guinea pig ventricular myocytes and to Ϫ20.7 mV as in the present study. Because no shift caused by coexpression of WT and A561V HERG proteins could be detected at ϩ35°C, one can suspect that the mutation alters the temperature sensitivity of the heteromeric channel activation. On the other hand, this discrepancy may be explained by the cell model difference (Chinese hamster ovary versus COS-7 cells).
Substitution of the alanine to a valine or a threonine at position 561 seems to have no effect on heteromeric channel activity. On the other hand, the substitution to a proline that may induce a kink in the S5 helix altered its activation and deactivation. By analogy to the Shaker channel structural model, Ala561 is the homolog of Shaker Val414 and faces the S1-S4 voltage sensor (Neale et al., 2003; Torres et al., 2003) . Mutations of amino acids facing the voltage-sensor may impair the intersubunit interactions and the coupling of the voltage-sensing function to the channel opening. In addition, S5 structure modification may also alter the pore stability. Finally, because the S4-S5 linker of HERG is involved in the voltage-dependence and kinetics of channel activation and deactivation, it can be suggested that mutations in the S5 helix may be the origin of the heteromeric channel behavior changes by simple allosteric changes, with repercussions on S4-S5 function. However, the activation modifications counterbalance the impaired trafficking consequences and overall lead to milder mutation effects.
Novel LQT2 Mutation. The penetrance of a mutation can be quite variable depending on the family but also among carriers in the same family, as reported for the A561V substitution (Priori et al., 1999) . In A561P gene carriers, the only symptom was the lengthening of the QT interval until the proband experienced the drug-induced torsades de pointes. As illustrated in the model simulation provided here, reduction of the resulting K ϩ current induces the AP lengthening responsible for the QT interval prolongation. Unlike the other Ala561 substitutions, the A561P mutation induced a more premature I Kr current that, despite its smaller amplitude, limits the AP duration prolongation. This difference from A561V or threonine mutation could, at least in part, explain the milder phenotype of A561P carriers.
Proarrhythmic Effect of Clobutinol. Because the torsades de pointes episode was independent of serum potassium, the drug may be supposed to be the direct trigger of the arrhythmia. Clobutinol has a renal elimination and no known metabolite (Zimmer et al., 1977) . The normal kidney function of the proband rules out a possible accumulation of the drug. As illustrated by the computer simulation, clobutinol has only a minor effect on the WT AP duration. Nevertheless, additive moderate reductions of I Kr , first by the HERG A561P mutation and then by clobutinol, may enhance heterogeneity in intrinsic electrophysiological properties among different ventricular cell types, an important determinant of the susceptibility to ventricular arrhythmias. Finally, our work shows that less severe mutation carriers are still at risk of developing arrhythmias when exposed to additional proarrhythmic drug or pathophysiological triggers.
It emphasizes the necessity of information on risk factors such as the QT Drug List provided by the University of Arizona Center for Education and Research on Therapeutics resuming the proarrhythmic drugs (http://www.qtdrugs. org/). The reported accident does not necessarily classify clobutinol in list 1 as a "drug with risk of torsades de pointes" but rather in list 3 listing "drugs to be avoided by congenital long QT patients".
